Browse
Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used
  
XBB.1.12.1NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
A.11NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
AY.22 (Delta)NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
BF.7.17NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
AY.123 (Delta)NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
BQ.1.27NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
BQ.1.1.71NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
BA.2.12.2NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
DN.1.1.3NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.177.51NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
BF.17NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
BA.2.28NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
XRNYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.350.1NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
XBF.1.1NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.343NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
AY.4.17 (Delta)NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
AY.25.1.2 (Delta)NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.1.409NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.1.83NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.1.310NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.362.1NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.1.162NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
Y.1NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
BA.2.38.1NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
XAVNYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
BE.1.4.4NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
XBC.1.3NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
BM.4.1NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
BF.20NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
BA.2.77NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
CP.1.3NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
FC.1NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
BY.1.2NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
AZ.2NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.1.97NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.36.18NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.177.32NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.1.59NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.177.67NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.277NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-1906.48Singapore
AY.28 (Delta)NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.1.272NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.1.371NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
AA.1NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.1.86NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.1.154NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.4.8NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
A.2.4NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.41NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used